Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
BNT324-03
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
- NCT07365995 ↗
- Recruiting
- BioNTech SE
- Focused
We haven't built an HCP commentary report on BNT324-03 (BNT324, Prednisone/prednisolone and 1 more in Metastatic Castration-resistant Prostate Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BNT324-03 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- BNT324; Docetaxel; Prednisone/prednisolone
- Arms
- BNT324 · Experimental
- Docetaxel plus prednisone/ prednisolone · Active comparator
- Enrollment
- 736 (estimated)
- Primary outcomes
- rPFS assessed by BICR
- OS
- Sponsor
- BioNTech SE with BioNTech (Shanghai) Pharmaceuticals Co., Ltd., DualityBio Inc.
- Start
- Apr 22, 2026
- Primary completion
- Feb 2031 (estimated)
- Results posted
- No
- Registry record
- NCT07365995 · updated Oct 16, 2026